Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Trial Status: Recruiting
Start Date: September, 2019
Expected Enrolment: 162
Type of Trial: Interventional
Protocol IDs: NCT03362177, 20140346, 2017-002992-25
Trial Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)
Trial Phase: Phase 3
Medical Conditions: Chemotherapy-induced Thrombocytopenia
Drugs: N/A
Lead Sponsor: Amgen
Sponsors/Study Groups: None specified
Type of Treatment:
  • Placebo
  • Biological: Romiplostim
Principal Investigator(s): MD, Amgen
Date posted on October 12, 2017
Last updated: February 6, 2022
This trial was imported from

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society